Delving into the Latest Updates on Epi Biotech Co., Ltd. with Synapse

概览

排名前五的药物类型	数量

细胞疗法	2
单克隆抗体	1
化学药	1

排名前五的靶点	数量

SDF-1(C-X-C基序趋化因子配体12)	1
AGA	1
RIPK1(受体相互作用的丝氨酸/苏氨酸蛋白激酶-1)	1

关联

5

项与 Epi Biotech Co., Ltd. 相关的药物

EPI-001(Epi Biotech)

靶点

AGA

作用机制

AGA inhibitors

在研机构

Epi Biotech Co., Ltd.

原研机构

Epi Biotech Co., Ltd.

在研适应症

脱发

非在研适应症-

最高研发阶段临床1/2期

首次获批国家/地区-

首次获批日期-

ΕΡΙ-008

靶点-

作用机制-

在研机构

Epi Biotech Co., Ltd.

原研机构

Epi Biotech Co., Ltd.

在研适应症

脱发

非在研适应症-

最高研发阶段临床前

首次获批国家/地区-

首次获批日期-

ΕΡΙ-002

靶点

RIPK1

作用机制

RIPK1抑制剂

在研机构

Epi Biotech Co., Ltd.

原研机构

Epi Biotech Co., Ltd.

在研适应症

脱发

非在研适应症-

最高研发阶段临床前

首次获批国家/地区-

首次获批日期-

100 项与 Epi Biotech Co., Ltd. 相关的临床结果

登录后查看更多信息

0 项与 Epi Biotech Co., Ltd. 相关的专利（医药）

登录后查看更多信息

20

项与 Epi Biotech Co., Ltd. 相关的文献（医药）

2024-03-01·Cell Proliferation

Involvement of DKK1 secreted from adipose‐derived stem cells in alopecia areata

Article

作者: Kim, Jino ; Choi, Nahyun ; Kim, Doo Yeong ; Sung, Jong-Hyuk ; Song, Seung Yong ; Hwang, Juyeong

AbstractAdipose‐derived stem cells (ASCs) have shown efficacy in promoting hair growth, while DKK1 inhibits the WNT pathway, which is associated with hair loss. Our study focused on investigating the expression of DKK1 in alopecia areata (AA), a condition characterised by significant increases in the DKK1 levels in human and mouse ASCs. Treatment of interferon‐γ increased the expression of DKK1 via STAT3 phosphorylation in ASCs. Treatment with recombinant DKK1 resulted in a decrease of cell growth in outer root sheath cells, whereas the use of a DKK1 neutralising antibody promoted hair growth. These results indicate that ASCs secrete DKK1, playing a crucial role in the progression and development of AA. Consequently, we generated DKK1 knockout (KO) ASCs using the Crispr/Cas9 system and evaluated their hair growth‐promoting effects in an AA model. The DKK1 KO in ASCs led to enhanced cell motility and reduced cellular senescence by activating the WNT signalling pathway, while it reduced the expression of inflammatory cytokines by inactivating the NF‐kB pathway. As expected, the intravenous injection of DKK1‐KO‐ASCs in AA mice, and the treatment with a conditioned medium derived from DKK1‐KO‐ASCs in hair organ culture proved to be more effective compared with the use of naïve ASCs and their conditioned medium. Overall, these findings suggest that DKK1 represents a novel therapeutic target for treating AA, and cell therapy using DKK1‐KO‐ASCs demonstrates greater efficiency.

2023-07-01·Experimental dermatology

Hair growth promoting effects of human dermal papilla cells in pig.

Letter

作者: Sung, Jong-Hyuk ; Hwang, Juyeong ; Zheng, Mei ; Kim, Hyunju ; Le, Trang Nu Huyen

Dermal papilla (DP) is important in maintaining the stem cell niche and stimulates the hair follicle (HF)′s re-entry into anagen during cycling.We observed microvessels around HF using immunohisto- chem. staining of CD31, and the number of microvessles around HF was increased in the hDPC- treated group ( Figure 1G ).However, repeated injection of hDPCs was not as effective as single injection (data not shown).These results collectively indicate that hDPCs in - creased the HF number, thickness and the angiogenesis in pig.In addition, single injection of hDPCs might be effective and survive for more than 3 mo in clin. study.

2022-06-01·Biomedicine & Pharmacotherapy2区 · 医学

CXCL12 inhibits hair growth through CXCR4

2区 · 医学

Article

作者: Oh, Sang Ho ; Kim, Jino ; Choi, Yong Jin ; Choi, Nahyun ; Sung, Jong-Hyuk ; Zheng, Mei

CXCL12 and its receptors, which are highly expressed in the skin, are associated with various cutaneous diseases, including androgenic alopecia. However, their expression and role during the hair cycle are unknown. This study aims to investigate the expression of CXCL12 and its receptor, CXCR4, in the vicinity of hair follicles and their effect on hair growth. CXCL12 was highly expressed in dermal fibroblasts (DFs) and its level was elevated throughout the catagen and telogen phases of the hair cycle. CXCR4 is expressed in the dermal papilla (DP) and outer root sheath (ORS). In hair organ culture, hair loss was induced by recombinant CXCL12 therapy, which delayed the telogen-to-anagen transition and decreased hair length. In contrast, the suppression of CXCL12 using a neutralizing antibody and siRNA triggered the telogen-to-anagen transition and increased hair length in hair organ culture. Neutralization of CXCR7, one of the two receptors for CXCL12, only slightly affected hair growth. However, inhibition of CXCR4, the other receptor for CXCL12, increased hair growth to a considerable extent. In addition, in hair organ culture, the conditioned medium from DFs with CXCL12 siRNA considerably increased the hair length and induced proliferation of DP and ORS cells. CXCL12, through CXCR4 activation, increased STAT3 and STAT5 phosphorylation in DP and ORS cells. In contrast, blocking CXCL12 and CXCR4 decreased the phosphorylation of STAT3 and STAT5. In summary, these findings suggest that CXCL12 inhibits hair growth via the CXCR4/STAT signaling pathway and that CXCL12/CXCR4 pathway inhibitors are a promising treatment option for hair growth.

100 项与 Epi Biotech Co., Ltd. 相关的药物交易

登录后查看更多信息

100 项与 Epi Biotech Co., Ltd. 相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

登录

或

查看完整样例数据

管线布局

2024年11月01日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

药物发现

1

2

临床前

临床2期

1

其他

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

EPI-001(Epi Biotech) ( AGA )	脱发更多	临床2期
ΕΡΙ-008	脱发更多	临床前
ΕΡΙ-002 ( RIPK1 )	脱发更多	临床前
EPI-005 ( SDF-1 )	脱发更多	药物发现
SM-002 ( ASK1 )	脱发更多	终止